Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.
paper
Cited
Public
Unavailable
- Authors
- Yamazaki, H; Inoue, K; Hashimoto, M; Shimada, T
- Year
- 1999
- Journal
- Archives of toxicology
- PMID
- 10350185
- DOI
- 10.1007/s002040050588
Nicotine C-oxidation by recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes was investigated using a convenient high-performance liquid chromatographic method. Experiments with recombinant human P450 enzymes in baculovirus systems, which co-express human nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH)-P450 reductase, revealed that CYP2A6 had the highest nicotine C-oxidation activities followed by CYP2B6 and CYP2D6; the Km values by these three P450 enzymes were determined to be 11.0, 105, and 132 microM, respectively, and the Vmax values to be 11.0, 8.2, and 8.6 nmol/min per nmol P450, respectively. CYP2E1, 2C19, 1A2, 2C8, 3A4, 2C9, and 1A1 catalysed nicotine C-oxidation only at high (500 microM) substrate concentration. CYP1B1, 2C18, 3A5, and 4A11 had no measurable activities even at 500 microM nicotine. In liver microsomes of 16 human samples, nicotine C-oxidation activities were correlated with CYP2A6 contents at 10 microM substrate concentration, whereas such correlation coefficients were decreased when the substrate concentration was increased to 500 microM. Contribution of CYP2B6 (as well as CYP2A6) was demonstrated by experiments with the effects of orphenadrine (and also coumarin and anti-CYP2A6) on the nicotine C-oxidation activities by human liver microsomes at 500 microM nicotine. CYP2D6 was found to have minor roles since quinidine did not inhibit microsomal nicotine C-oxidation at both 10 and 500 microM substrate concentrations. These results support the view that CYP2A6 has major roles for nicotine C-oxidation at lower substrate concentration and both CYP2A6 and 2B6 play roles at higher substrate concentrations in human liver microsomes.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Development of a Physiologically Based Pharmacokinetic (PBPK) Simulation Model for Nicotine. | Kim B et al. | — | 2025 | → |
| Engineering <i>Bacillus</i> Spores to Display Nicotine Oxidase: In Situ Specific and Sensitive Nicotine Detection. | Xiong X et al. | — | 2025 | → |
| The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure. | Zhang M et al. | — | 2024 | → |
| Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers. | Perez-Paramo YX et al. | — | 2023 | → |
| Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD). | Nasrin S et al. | — | 2023 | → |
| Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. | Marie S et al. | — | 2023 | → |
| Cytochrome P450 enzymes and metabolism of drugs and neurotoxins within the mammalian brain. | Stocco MR et al. | — | 2022 | → |
| Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation. | Li H et al. | — | 2022 | → |
| Protective action of polysaccharides from Laurencia papillose (Rhodophyta) against imidacloprid induced genotoxicity and oxidative stress in male albino rats. | Abdelhafez HEDH et al. | — | 2022 | → |
| Biochemistry of nicotine metabolism and its relevance to lung cancer. | Murphy SE | — | 2021 | → |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | — | 2021 | → |
| Comprehensive Parent-Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy Strategies. | Kovar L et al. | — | 2020 | → |
| Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde. | Espiritu MJ et al. | — | 2020 | → |
| Nicotine Monitoring with a Wearable Sweat Band. | Tai LC et al. | — | 2020 | → |
| Comparison of smoking-related DNA methylation between newborns from prenatal exposure and adults from personal smoking. | Sikdar S et al. | — | 2019 | → |
| Molecular mechanisms for nicotine intoxication. | Alkam T et al. | — | 2019 | → |
| A CYP2B6-humanized mouse model and its potential applications. | Li L et al. | — | 2018 | → |
| Antioxidant capacity of omega-3-fatty acids and vitamin E against imidacloprid-induced hepatotoxicity in Japanese quails. | Emam H et al. | — | 2018 | → |
| Computational Understanding of the Selectivities in Metalloenzymes. | Wei WJ et al. | — | 2018 | → |
| Distribution of <i>CYP2B6 516G/T</i> pharmacogenetically important polymorphism in the Ukrainian population. | Filiptsova O et al. | — | 2018 | → |
| Genetic Polymorphism of <i>CYP2A6</i> and Its Relationship with Nicotine Metabolism in Male Bataknese Smokers Suffered from Lung Cancer in Indonesia. | Soeroso NN et al. | — | 2018 | → |
| Meta-analysis update of association between dopamine transporter SLC6A3 gene polymorphism and smoking cessation. | Choi HD et al. | — | 2018 | → |
| Brain CYP2B induction can decrease nicotine levels in the brain. | Garcia KLP et al. | — | 2017 | → |
| Influence of alpha-lipoic acid on nicotine-induced lung and liver damage in experimental rats. | Ateyya H et al. | — | 2017 | → |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | — | 2017 | → |
| Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs. | Toselli F et al. | — | 2016 | → |
| Evaluation of Serum Cotinine Cut-Off to Distinguish Smokers From Nonsmokers in the Korean Population. | Ko K et al. | — | 2016 | → |
| Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. | Leger P et al. | — | 2016 | → |
| Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. | Allenby CE et al. | — | 2016 | → |
| Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. | Backman JT et al. | — | 2016 | → |
| A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. | Loukola A et al. | — | 2015 | → |
| A penalized robust semiparametric approach for gene-environment interactions. | Wu C et al. | — | 2015 | → |
| Characterization of CYP2B6 in a CYP2B6-humanized mouse model: inducibility in the liver by phenobarbital and dexamethasone and role in nicotine metabolism in vivo. | Liu Z et al. | — | 2015 | → |
| Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. | Ford KA et al. | — | 2015 | → |
| CYP2B6 gene single-nucleotide polymorphisms in an Italian population sample and relationship with nicotine dependence. | Riccardi LN et al. | — | 2015 | → |
| Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. | Kumar S et al. | — | 2015 | → |
| Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. | Garcia KL et al. | — | 2015 | → |
| Effect of genotype and methylation of CYP2D6 on smoking behaviour. | Tiili EM et al. | — | 2015 | → |
| N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort. | LeMasters GK et al. | — | 2015 | → |
| Oxidative damage and histopathological changes in lung of rat chronically exposed to nicotine alone or associated to ethanol. | Dhouib H et al. | — | 2015 | → |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | — | 2015 | → |
| "Target-Site" Drug Metabolism and Transport. | Foti RS et al. | — | 2015 | → |
| A glimpse into the future - Personalized medicine for smoking cessation. | Bierut LJ et al. | — | 2014 | → |
| Allele and genotype frequencies of CYP2B6 in a Turkish population. | Yuce-Artun N et al. | — | 2014 | → |
| Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity. | Yamamiya I et al. | — | 2014 | → |
| Influence of CYP2A6*4 genotypes on maternal serum cotinine among Chinese nonsmoking pregnant women. | Xie C et al. | — | 2014 | → |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | Demers CH et al. | — | 2014 | → |
| Advances in molecular modeling of human cytochrome P450 polymorphism. | Martiny VY et al. | — | 2013 | → |
| Association of CYP2A6*4 with susceptibility of lung cancer: a meta-analysis. | Wang L | — | 2013 | → |
| Catalytic mechanism of cytochrome P450 for N-methylhydroxylation of nicotine: reaction pathways and regioselectivity of the enzymatic nicotine oxidation. | Li D et al. | — | 2013 | → |
| Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. | Cortes CP et al. | — | 2013 | → |
| CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. | Liu YL et al. | — | 2013 | → |
| Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. | Zanger UM et al. | — | 2013 | → |
| Identification of cytochrome P450 isoenzymes involved in metabolism of (+)-praeruptorin A, a calcium channel blocker, by human liver microsomes using ultra high-performance liquid chromatography coupled with tandem mass spectrometry. | Jing WH et al. | — | 2013 | → |
| Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse. | Li L et al. | — | 2013 | → |
| Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. | Zanger UM et al. | — | 2013 | → |
| Analysis of nicotine-induced DNA damage in cells of the human respiratory tract. | Ginzkey C et al. | — | 2012 | → |
| Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys. | Ferguson CS et al. | — | 2012 | → |
| Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. | Nakada T et al. | — | 2012 | → |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | — | 2012 | → |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | — | 2012 | → |
| A novel biotransformation of alkyl aminopyrrolidine to aminopiperidine ring by human CYP3A. | Chen Y et al. | — | 2011 | → |
| Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. | Li D et al. | — | 2011 | → |
| Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. | Washio I et al. | — | 2011 | → |
| Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. | Wyen C et al. | — | 2011 | → |
| Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. | Ferguson CS et al. | — | 2011 | → |
| Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites. | Koyama N et al. | — | 2011 | → |
| Ethanol induction of CYP2A5: permissive role for CYP2E1. | Lu Y et al. | — | 2011 | → |
| Genetic vulnerability and susceptibility to substance dependence. | Bierut LJ | — | 2011 | → |
| Identification of novel CYP2A6 inhibitors by virtual screening. | Rahnasto MK et al. | — | 2011 | → |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | — | 2011 | → |
| The novel assay method for nicotine metabolism to cotinine using high performance liquid chromatography. | Miyazawa M et al. | — | 2011 | → |
| Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. | Heravi RE et al. | — | 2010 | → |
| Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. | Nagano T et al. | — | 2010 | → |
| Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine. | Li D et al. | — | 2010 | → |
| Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. | Al Koudsi N et al. | — | 2010 | → |
| Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. | Al Koudsi N et al. | — | 2010 | → |
| Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. | Yamazaki H et al. | — | 2010 | → |
| Indicators of oxidative stress in weanling and pubertal rats following exposure to nicotine via milk. | Halima BA et al. | — | 2010 | → |
| Neural markers of genetic vulnerability to drug addiction. | Müller DJ et al. | — | 2010 | → |
| Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. | Zhou X et al. | — | 2010 | → |
| Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. | Zhou SF et al. | — | 2010 | → |
| The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: a randomized controlled trial in unmotivated smokers. | Hussain S et al. | — | 2010 | → |
| A review of smoking behavior and smokers evidence (chemical modification, inducing nicotine metabolism, and individual variations by genotype: dopaminergic function and personality traits). | Iwahashi K et al. | — | 2009 | → |
| Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. | Murai K et al. | — | 2009 | → |
| Effects of nicotine exposure on in vitro metabolism of chlorpyrifos in male Sprague-Dawley rats. | Lee S et al. | — | 2009 | → |
| Human hepatic CYP2B6 developmental expression: the impact of age and genotype. | Croom EL et al. | — | 2009 | → |
| Metabolic interactions with piperazine-based 'party pill' drugs. | Antia U et al. | — | 2009 | → |
| Molecular genetics of nicotine metabolism. | Mwenifumbo JC et al. | — | 2009 | → |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | — | 2009 | → |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | — | 2009 | → |
| The role of african american ethnicity and metabolism in sentinel polychlorinated biphenyl congener serum levels. | McGraw JE et al. | — | 2009 | → |
| CYP2A6 polymorphisms and risk for tobacco-related cancers. | Rossini A et al. | — | 2008 | → |
| Effect of quercetin on nicotine-induced biochemical changes and DNA damage in rat peripheral blood lymphocytes. | Muthukumaran S et al. | — | 2008 | → |
| Influence of ferulic acid on nicotine-induced lipid peroxidation, DNA damage and inflammation in experimental rats as compared to N-acetylcysteine. | Sudheer AR et al. | — | 2008 | → |
| Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. | Sharma G et al. | — | 2008 | → |
| Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. | Siu EC et al. | — | 2007 | → |
| CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. | Lee AM et al. | — | 2007 | → |
| CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. | Lee AM et al. | — | 2007 | → |
| Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. | von Weymarn LB et al. | — | 2007 | → |
| Ellagic acid, a natural polyphenol protects rat peripheral blood lymphocytes against nicotine-induced cellular and DNA damage in vitro: with the comparison of N-acetylcysteine. | Sudheer AR et al. | — | 2007 | → |
| Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. | Ring HZ et al. | — | 2007 | → |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | — | 2007 | → |
| Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. | Murayama N et al. | — | 2007 | → |
| Non-nicotinic therapies for smoking cessation. | Siu EC et al. | — | 2007 | → |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | — | 2007 | → |
| Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. | Zanger UM et al. | — | 2007 | → |
| Protective effect of ferulic acid on nicotine-induced DNA damage and cellular changes in cultured rat peripheral blood lymphocytes: a comparison with N-acetylcysteine. | Sudheer AR et al. | — | 2007 | → |
| CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. | Lee AM et al. | — | 2006 | → |
| Effect of sulfur dioxide inhalation on CYP2B1/2 and CYP2E1 in rat liver and lung. | Qin G et al. | — | 2006 | → |
| Effects of benzyl and phenethyl isothiocyanate on P450s 2A6 and 2A13: potential for chemoprevention in smokers. | von Weymarn LB et al. | — | 2006 | → |
| Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. | von Weymarn LB et al. | — | 2006 | → |
| Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. | Lee AM et al. | — | 2006 | → |
| Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. | Hesse LM et al. | — | 2006 | → |
| Tailoring nicotine replacement therapy: rationale and potential approaches. | McClure JB et al. | — | 2006 | → |
| Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. | Jalas JR et al. | — | 2005 | → |
| Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. | Wu ZL et al. | — | 2005 | → |
| Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. | Zhang QY et al. | — | 2005 | → |
| Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. | Klein K et al. | — | 2005 | → |
| Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. | Nakajima M et al. | — | 2005 | → |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | — | 2005 | → |
| Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. | Murphy SE et al. | — | 2005 | → |
| Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. | Dicke KE et al. | — | 2005 | → |
| Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. | Swan GE et al. | — | 2005 | → |
| Porcine CYP2A polymorphisms and activity. | Skaanild MT et al. | — | 2005 | → |
| A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers. | Murphy SE et al. | — | 2004 | → |
| Effects of "second-hand" smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. | Wong LS et al. | — | 2004 | → |
| Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. | Hatsukami DK et al. | — | 2004 | → |
| Genetics of tobacco use. | Maserejian NN et al. | — | 2004 | → |
| Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. | Yamanaka H et al. | — | 2004 | → |
| Metabolism and biochemical effects of nicotine for primary care providers. | Metz CN et al. | — | 2004 | → |
| Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. | Lang T et al. | — | 2004 | → |
| Postnatal expression of cytochrome P450 1A1, 2A3, and 2B1 mRNA in neonatal rat lung: influence of maternal nicotine exposure. | Gamieldien K et al. | — | 2004 | → |
| Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. | Richter T et al. | — | 2004 | → |
| The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. | Miksys S et al. | — | 2004 | → |
| Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior. | Iwahashi K et al. | — | 2004 | → |
| Clinical considerations in study designs that use cotinine as a biomarker. | Bramer SL et al. | — | 2003 | → |
| Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. | Schoedel KA et al. | — | 2003 | → |
| Effects of nicotine infusion on the metabolism of the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in rats. | Keyler D et al. | — | 2003 | → |
| Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. | Schoedel KA et al. | — | 2003 | → |
| Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. | Tricker AR | — | 2003 | → |
| Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. | Tyndale RF et al. | — | 2002 | → |
| Pharmacogenetic investigation of smoking cessation treatment. | Lerman C et al. | — | 2002 | → |
| Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. | Yamazaki H et al. | — | 2002 | → |
| Summary of information on human CYP enzymes: human P450 metabolism data. | Rendic S | — | 2002 | → |
| cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. | Domanski TL et al. | — | 2001 | → |
| CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. | Kitagawa K et al. | — | 2001 | → |
| Determination of coumarin metabolism in Turkish population. | Cok I et al. | — | 2001 | → |
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. | Lang T et al. | — | 2001 | → |
| Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. | Schoedel KA et al. | — | 2001 | → |
| Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. | Asano T et al. | — | 2001 | → |
| Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. | Hoffman SM et al. | — | 2001 | → |
| Polymorphisms of CYP2A6 and its practical consequences. | Raunio H et al. | — | 2001 | → |
| 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. | Hecht SS et al. | — | 2000 | → |
| Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. | Bendriss EK et al. | — | 2000 | → |
| Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. | Oscarson M et al. | — | 1999 | → |
| The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. | Kitagawa K et al. | — | 1999 | → |